BridgeBio Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for BridgeBio Pharma (BBIO).

Price Target Range — 10 Quarters

Analyst Consensus — 25 Analysts

23Buy

2Hold

Consensus RatingBuy# Analysts25Avg. Consensus PT$94Upside to Avg. PT+38.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 19, 2026	Piper Sandler	Biren Amin	PT Raise	Overweight	$115→$120
Oct 15, 2026	UBS	Joon Lee	Assumes	Buy	$82→$92
Oct 7, 2026	Barclays	Eliana Merle	PT Cut	Overweight	$157→$156
Sep 10, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$120
Sep 2, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$120
Sep 1, 2026	Mizuho	Salim Syed	PT Raise	Outperform	$96→$110
Aug 12, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$102→$107
Aug 12, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$104→$106
Aug 12, 2026	JP Morgan	Anupam Rama	PT Raise	Overweight	$100→$111
Aug 11, 2026	B of A Securities	Geoff Meacham	PT Raise	Buy	$101→$104
Aug 11, 2026	TD Cowen	Tyler Van Buren	PT Raise	Buy	$95→$110
Aug 11, 2026	Morgan Stanley	Sean Laaman	PT Cut	Overweight	$98→$97
Aug 11, 2026	Piper Sandler	Biren Amin	PT Raise	Overweight	$111→$115
Aug 11, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$98→$102
Jul 16, 2026	Citigroup	Eric Joseph	PT Raise	Neutral	$82→$93
Jul 13, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$110→$120
Jun 16, 2026	Mizuho	Salim Syed	PT Cut	Outperform	$106→$96
Jun 3, 2026	Canaccord Genuity	Whitney Ijem	Initiate	Buy	$104
May 28, 2026	Morgan Stanley	Sean Laaman	PT Raise	Overweight	$94→$98
May 28, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$110

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120

Piper Sandler analyst Biren Amin maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $115 to $120.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156

Barclays analyst Eliana Merle maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $157 to $156.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $120 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $120 price target.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on BridgeBio Pharma, Raises Price Target to $110

Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target from $96 to $110.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $107

Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $102 to $107.

Benzinga Newsdesk

BridgeBio Pharma Inc

BridgeBio Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120

PRO
Barclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156

PRO
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

PRO
Mizuho Maintains Outperform on BridgeBio Pharma, Raises Price Target to $110

PRO
Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $107

People Also Watch

People Also Watch

BridgeBio Pharma Inc

BridgeBio Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROPiper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120

PROBarclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156

PROHC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

PROHC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

PROMizuho Maintains Outperform on BridgeBio Pharma, Raises Price Target to $110

PROTruist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $107

People Also Watch

People Also Watch

PRO
Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120

PRO
Barclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156

PRO
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

PRO
Mizuho Maintains Outperform on BridgeBio Pharma, Raises Price Target to $110

PRO
Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $107